2009/09/14 by Marcia F.T. Rupnow, Alicia H. Chang, Ross D. Shachter +2 · 3 citations
Medicine · #Helicobacter pylori-related gastroenterology studies #Gastroesophageal reflux and treatments #Eosinophilic Esophagitis #Medicine #Vaccination #Helicobacter pylori #Cost effectiveness #Population #Quality-adjusted life year #Vaccine efficacy #Cost-effectiveness analysis #Cost–benefit analysis #Incremental cost-effectiveness ratio #Pediatrics #Demography #Environmental health #Immunology #Internal medicine #Biology
paper · doi:10.1086/605845
openalex publication_date 2009/09/14 · openalex created_date 2025/10/10 · openalex updated_date 2026/06/24
Helicobacter pylori vaccines are under development to prevent infection. We quantified the cost-effectiveness of such a vaccine in the United States, using a dynamic transmission model.We compartmentalized the population by age, infection status, and clinical disease state and measured effectiveness in quality-adjusted life years (QALYs). We simulated no intervention, vaccination of infants, and vaccination of school-age children. Variables included costs of vaccine, vaccine administration, and gastric cancer treatment (in 2007 US dollars), vaccine efficacy, quality adjustment due to gastric cancer, and discount rate. We evaluated possible outcomes for periods of 10-75 years.H. pylori vaccination of infants would cost 2.9 billion over 10 years; savings from cancer prevention would be realized decades later. Over a long time horizon (75 years), incremental costs of H. pylori vaccination would be 1.8 billion, and incremental QALYs would be 0.5 million, yielding a cost-effectiveness ratio of 3871/QALY. With school-age vaccination, the cost-effectiveness ratio would be 22,137/QALY. With time limited to <40 years, the cost-effectiveness ratio exceeded 50,000/QALY.When evaluated with a time horizon beyond 40 years, the use of a prophylactic H. pylori vaccine was cost-effective in the United States, especially with infant vaccination.